Clinical Trial Update: Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a peptide vaccine targeting driver oncogenes in combination with durvalumab and tremelimumab for biliary tract cancers; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Peptide vaccine targeting driver oncogenes
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Biliary Tract Cancers | Phase 1 | Status: RECRUITING